Related Experiment Video
Updated: Apr 19, 2026
23:53
Ole Isacson: Development of New Therapies for Parkinson's Disease
Published on: April 29, 2007
8.5K
Initial management of Parkinson's disease
Christopher G Goetz1, Gian Pal2
1Department of Neurological Sciences, Rush University Medical Center, Chicago, IL 60612, USA.
BMJ (Clinical Research Ed.)
|December 21, 2014
Summary
Parkinson's disease involves brain cell degeneration and dopamine deficiency. Current treatments manage motor symptoms but do not halt disease progression, necessitating careful drug selection for Parkinson's patients.
Area of Science:
- Neurology
- Neuroscience
- Pharmacology
Background:
- Parkinson's disease (PD) is a prevalent neurodegenerative disorder in the US and UK.
- PD is characterized by cellular degeneration and dopamine deficiency, treated separately in clinical practice.
- No definitive neuroprotective or disease-modifying treatments currently exist for Parkinson's disease.
Purpose of the Study:
- To review current approaches to managing Parkinson's disease.
- To emphasize the importance of strategic agent selection for treating motor symptoms.
- To highlight the need for addressing non-motor symptoms in Parkinson's disease management.
Main Methods:
- Review of current therapeutic strategies for Parkinson's disease.
- Analysis of factors influencing the choice of dopaminergic agents.
- Consideration of both motor and non-motor symptoms in treatment.
Main Results:
- Several agents effectively manage motor symptoms associated with dopamine deficiency.
- Drug selection requires careful consideration of potency, patient goals, comorbidities, and short/long-term implications.
- Non-motor symptoms like depression and sleep disorders require evaluation and treatment.
- Research into improved dopaminergic delivery is ongoing.
- Studies on disease progression modification have not yielded promising results.
Conclusions:
- Effective management of Parkinson's disease involves treating both motor and non-motor symptoms.
- Optimizing dopaminergic therapy and careful agent selection are crucial.
- Further research is needed for neuroprotective and disease-modifying Parkinson's treatments.
Related Concept Videos
01:24Parkinson's Disease: Treatment
1.4K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.4K
01:15Parkinson's Disease: Overview
2.5K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.5K
01:24Parkinson Disease l: Introduction
5
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of...
5
01:24Parkinson Disease ll: Pathophysiology
6
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
6
01:11Alterations in Muscle Tone lll
5
Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...
5
01:22Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K